Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: TheBusDriver who wrote (12810)	8/23/2003 2:28:32 AM
From: Montana Wildhack	Read Replies (3) \| Respond to of 14101

They're sapping my bodily essence, Mandrake. So they had cash problems without any revenue and now they have cash problems with revenue. The RO was reported as $9.2 million on April 03 but appears to be $5.9 million in this report. I don't get that. The inventories and accounts receivable jumped in line with the reported $433 vs $83 sales in Pennsaid and ramping up of Pennsaid activity. GP moved to 53% from the 18% prior year and was 57% in the 4th quarter up from the 43% for the first 9 months. That's a good indicator that with more sales in the next quarter, the GP should shoot up again. It should become clearer on the next statements with this August quarter end in the can before the AGM what trend the Pennsaid sales are in. My opinion is to accept the 7,000 prescription number in May and June as valid. The decision to be practical back then didn't factor in the setbacks from the expected timetables that hindsight now makes so clear and this was discussed at length. Take the cash when its available - not when you actually need it. So now even as the first signs of Pennsaid in its new markets is positive and both sales overall and GP have jumped - the focus remains on cash and leadership. It's a perfectly lovely little war and we can hope that no one has actually torn their hair out living through it.